Literature DB >> 18559565

Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray.

Amanda Psyrri1, Brian Egleston, Paul Weinberger, Ziwei Yu, Diane Kowalski, Clarence Sasaki, Bruce Haffty, David Rimm, Barbara Burtness.   

Abstract

BACKGROUND: We have previously reported nuclear localization of epidermal growth factor receptor (EGFR) protein in oropharyngeal cancer tissue. Nuclear EGFR levels were inversely correlated with survival and response to radiotherapy. Here, we sought to identify the determinants and correlates of nuclear EGFR content.
METHODS: We analyzed an oropharyngeal cancer tissue microarray for the expression of the key molecules of the EGFR signaling cascade using an automated image analysis technique (AQUA) scored on a scale of 0 to 255, which permits protein quantitation and subcellular localization. Patients with oropharyngeal squamous cell cancer treated with radiotherapy or surgery and radiotherapy were eligible. Data were analyzed using Spearman correlations and multiple linear regression with robust SEs.
RESULTS: Of the 95 tumors included in this study, 72 (75%) had sufficient tissue for analysis of nuclear EGFR. Nuclear EGFR levels were associated with membranous/cytoplasmic EGFR levels (rho = 0.82, P < 0.001), nuclear extracellular signal-regulated kinase-2 (rho = 0.30, P = 0.01), and nuclear proliferating cell nuclear antigen (PCNA; rho = 0.36, P = 0.003). Nuclear phosphorylated-Akt, cyclin D1, phosphatase and tensin homolog (mutated in multiple cancers 1) (PTEN), p53, and proliferation marker Ki-67 levels did not correlate with nuclear EGFR level. In multivariable analysis, only PCNA retained its significant association (P = 0.01).
CONCLUSIONS: These results are consistent with preclinical data showing that EGFR may function as a tyrosine kinase in the nucleus, phosphorylating and stabilizing PCNA. The nuclear activity of EGFR may constitute a novel therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559565     DOI: 10.1158/1055-9965.EPI-07-2684

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  20 in total

Review 1.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII.

Authors:  Anupama E Gururaj; Laura Gibson; Sonali Panchabhai; MingHui Bai; Ganiraju Manyam; Yue Lu; Khatri Latha; Marta L Rojas; Yeohyeon Hwang; Shoudan Liang; Oliver Bogler
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 3.  On mammary gland growth factors: roles in normal development and in cancer.

Authors:  Mien-Chie Hung
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

4.  Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.

Authors:  Yung-Luen Yu; Ruey-Hwang Chou; Chia-Han Wu; Ying-Nai Wang; Wei-Jung Chang; Yen-Ju Tseng; Wei-Chao Chang; Chien-Chen Lai; Hong-Jen Lee; Longfei Huo; Chung-Hsuan Chen; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 5.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

6.  Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2.

Authors:  Ying-Nai Wang; Heng-Huan Lee; Hong-Jen Lee; Yi Du; Hirohito Yamaguchi; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

Review 7.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

Review 8.  Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.

Authors:  Shao-Chun Wang; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

9.  Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.

Authors:  Andrés López-Albaitero; Steve C Lee; Sarah Morgan; Jennifer R Grandis; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2009-03-25       Impact factor: 6.968

10.  Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.

Authors:  Anna Sukhanova; Andrey Gorin; Ilya G Serebriiskii; Linara Gabitova; Hui Zheng; Diana Restifo; Brian L Egleston; David Cunningham; Tetyana Bagnyukova; Hanqing Liu; Anna Nikonova; Gregory P Adams; Yan Zhou; Dong-Hua Yang; Ranee Mehra; Barbara Burtness; Kathy Q Cai; Andres Klein-Szanto; Lisa E Kratz; Richard I Kelley; Louis M Weiner; Gail E Herman; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Discov       Date:  2012-11-02       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.